Types of Steroids: Nandrolone Analogues or Dihydrotestosterone Derivatives

There essentially exists only one Nandrolone derivative that is conventionally and commercially available: Trenbolone. Although other Nandrolone analogues have been developed, they are not commonly known and are not very popular for one reason or another. Nandrolone itself cannot technically be counted, as it is not a derivative – it IS Nandrolone. Therefore, the only Nandrolone analogue of question here is Trenbolone.

Nandrolone and Tren belong to a special unique category of anabolic steroids known as Progestins. Nandrolone itself is quite structurally similar to Testosterone. However, Nandrolone differs from Testosterone due to the lack of the 19th carbon. This is why Nandrolone and Trenbolone are often referred to as 19-nortestosterone compounds, meaning a carbon atom is missing at the 19th position. As such, any compound relating to (or is a derivative of) Nandrolone is also commonly referred to as a ’19-nor’ compound, including Nandrolone itself.

Trenbolone being a Nandrolone derivative is of course missing the aforementioned carbon atom at the 19th position (which is in reality a whole methyl group) and this carbon atom is instead replaced by double-bonds between the two carbon atoms that the 19th carbon was originally bound with (this
differs from Nandrolone where the lacking 19th carbon is simply replaced with a hydrogen atom instead of double-bonds in Trenbolone’s case). This lack of a 19th carbon is what increases the resistance of 19-nor compounds to interaction with the aromatase enzyme and therefore very resistant to any Estrogen conversion – however, this is not the whole story for Trenbolone when it comes to aromatization. Trenbolone also contains modifications at carbons 19 and 11, where one hydrogen atom was removed from each carbon so that carbons 19 and 11 become double-bonded with their neighboring carbon atoms in their respective cycloalkane rings. These additional modifications of double-bonds at carbon 19 and 11 are what provides Trenbolone not just increased resistance to aromatization, but to become completely immune to it and be unable to interact what so ever with the aromatase enzyme. These different modifications are also responsible for granting Trenbolone with the extreme anabolic and androgenic strength ratings it is so well known for.

19-nor Progestational compounds such as Nandrolone and Trenbolone exhibit various effects and side effects in the body that are unique only to 19-nor compounds, and are not seen among any other types of steroids. Studies have demonstrated that 19-nor anabolic steroids tend to exhibit binding affinity for the Progesterone receptors in the body. Trenbolone in particular possesses very strong binding affinity (much stronger than Nandrolone) for the Progesterone receptor 1. As mentioned above, this is one of the factors involved where Trenbolone possesses side effects that are almost never seen in other anabolic steroids that are not Progestins. Progestogenic side effects are almost identical to Estrogenic side effects, and they include: severe endogenous Testosterone production shutdown/suppression, gynecomastia, and water retention. It has been determined that the activity of Progestins is closely correlated with the activity of Estrogen in the body. This is why care must be taken to understand the Progestogenic properties of Nandrolone and its derivatives before using them, as well as how to properly deal with the associated Progestogenic effects.

19-nor compounds (Nandrolone derivatives) are preferred by athletes and bodybuilders for many of the same reasons that they would prefer DHT derivatives. 19-nor compounds are either highly resistant to aromatization, or do not aromatize into Estrogen at all (in Trenbolone’s case), and therefore eliminate the potential for Estrogen-related side effects such as water retention/bloating and gynecomastia. These types of steroids also do not interact with the 5AR enzyme, or they interact with it in very miniscule amounts (in Nandrolone’s case). However, Progestogenic effects are a concern that must be fully understood. For a further in-depth description of what these Progestin effects are, please refer to the specific profiles for both Nandrolone as well as Trenbolone where this is delved into greater detail.

GHRP-2 & GHRP-6: Injectable Growth Hormone Releasing Hexapeptides

Getting straight to the point, GHRP signals the pituitary to secrete GH. This action offers a lot of benefits, which will be covered later. It's also worth mentioning that there are various types of GHRPs, however, this particular discussion revolves around GHRP-2 and GHRP-6.

How do GHRP-2 and GHRP-6 differ from Each Other?
While both of these amino acid peptides release GH, there's a noticeable difference in GHRP-6, which speeds up digestion allowing for larger consumption of food. It's worth adding that this particular peptide is a first-generation GHRP.

What distinguishes GHRP-2 is its ability to cause growth hormone to be released more intensely. This second-generation GHRP is best for those who want to get the absolute most value from the GH releases. On the other hand, if increasing low appetite is the main concern GHRP-6 would be best.

What Other Benefits do GHRP-2 and GHRP-6 provide?
Just one dose of GHRP can battle aging effects, improve sleep quality and repair small injuries. So in short, taking these amino acid peptides will greatly improve life and overall health.

The best time to administer a dose is right before bed since this is the period when the pituitary is most active. Some researchers administer multiple doses in a day because this can help build lean muscle tissue and promote fat loss.

If the Goal of this research peptide is fat loss, how should GHRP be used?
ghrp_6 One possible way is to use GHRP an hour before cardio, when the stomach is empty. Afterward, one isn't to eat for another two hours so that the body uses fat stores as fuel. But keep in mind that this method of promoting fat loss with GHRP is debatable.

Why not just use Growth Hormone Instead?
For starters, not all GH is pure. Many researchers have been burned when they spend a fortune to order GH from China and other countries, thinking all along that they're getting the real thing. But what they get instead is a counterfeit kit that only contains a fractional amount of GH or just HCG powder.

Growth Hormone Releasing Hormone CJC-1295

It increases protein synthesis and stimulates the growth of new muscle tissue.

- Allows for normal growth in short children with GH deficiency.
- Increases muscle mass (and physical strength if combined with moderate exercise).
- Reduces wrinkling of the skin and some other effects of skin aging.
- Re-grows internal organs that have atrophied with age.
- Causes hyperplasia, the increase of more muscle cells.
- It increases muscle mass through the creation of new muscle cells (which differs from hypertrophy).
- It promotes lipolysis, which results in the reduction of adipose tissue (body fat).
- Increased bone density.
- Faster recovery from exercise, exertion, and injuries.
- Strengthen the immune system.

It is important to begin the discussion of CJC-1295 with a discussion of the parent of the Growth Hormone Releasing Factors which is somatocrinin., this peptide ultimately gave birth to the newer generations of Growth-hormone-releasing hormone peptides (CJC-1295).

Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin, is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus. GHRH is released from neurosecretory nerve terminals of these arcuate neurons, and is carried by the hypothalamo-hypophysial portal circulation to the anterior pituitary gland where it stimulates growth hormone secretion. GHRH stimulates the production of growth hormone.

GHRH gave birth to a more compact growth hormone releasing factor known as Sermorelin which is a synthetic analogue of growth hormone releasing hormone, which is produced by the hypothalamus. Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.

So, what was the problem with Sermorelin, or GHRH for that matter? The clinical use of growth hormone-releasing hormone (GHRH) is limited by its short half-life. Also it follows that Sermorelin faced the same difficulties and thus is limited by its short half life (approximately 12 min following intravenous injection in humans), mainly due to its susceptibility to rapid enzymatic degradation. Thus, the product quickly dissipated in the body and the peptide could not stay in the body long enough to have a medicinal impact. A Munafo, T X Q Nguyen, O Papasouliotis, H L?cuelle, A Priestley and M O Thorner (2005). There were attempts to resolve some of the short half-life issues with Sermorelin, in fact a PEGylated GHRH was developed. Even though PEGylated GHRH solved some of the degradation issues, the much more potent CJC 1295, rendered PEGylated GHRH obsolete.

Instead of using a PEGylated technology, the technology of bioconjugation was employed. In vivo bioconjugation to serum albumin is a useful tool to increase the half-life of small molecules or peptides in plasma. In vivo bioconjugation occurs when a strategically placed reactive group on a bioactive peptide reacts with a nucleophilic entity found in blood or in sc interstitium to form a stable bond. The foremost nucleophile is the thiol, and its most abundant source in these fluids is Cys34 on albumin. The thiol on Cys34 reacts with a Michael acceptor, such as a maleimido derivative, leading to a new bioactive protein construct that will adopt an extended half-life due to stabilization from enzymatic degradation) or reduced elimination through the kidney. It therefore became logical to combine the long-lasting effect of bioconjugation with the proper GRF analog. Lucie Jett?, Roger L?ger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, V?ronique Paradis, Pieter van Wyk, Khan Pham and Dominique P. Bridon (2005).

CJC-1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days. Bioconjugation takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin.

So how effective is bioconjugation? How long will CJC-1295 stay in ones system? How will CJC-1295 impact IGF-1 levels? This is the exact question researchers asked and a study was conducted to determine the efficacy of CJC-1295. The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 days. Healthy subjects, ages 21-61 years old were studied. After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. The estimated half-life of CJC-1295 was 5.8-8.1 days. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days. No serious adverse reactions were reported. Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne and Lawrence A. Frohman (2006). What was the research dose used in the study? A particularly important question, the dosage was 30-60 micrograms per kilogram of bodyweight.

This bears repetition, GH remained elevated for up to six days! IGF-1 concentrations were up 1.5 to 3 fold for 9-11 days! And the estimated half-life of CJC-1295 is 5.8-8.1 days! IGF-1 levels were elevated up to 28 days! At a dosage of 30-60 micrograms per kilogram of bodyweight, with no significant side effects. Excuse all he emphasis but this is a truly remarkable research product, its ability for efficacy is self-evident.

So in sum, what is CJC-1295? CJC-1295 is a long-acting analog of GH-releasing hormone. CJC-1295 exhibits the same effects of Human Growth Hormone, it has the ability to promote muscle mass, increase bone density, improve protein synthesis, increase IGF-1 levels potently, strengthen immune systems, stimulate the production of bone marrow cells that produce red blood cells, and of course reduce excess body fat, especially abdominal fat. (The reduction of abdominal fat is the single most profound effect of HGH replacement.)

Peptide should be administered at least twice a week (so divide the research dose into two administrations on your research subject) this will help to keep blood levels consistent in your research subject, or in cellular culture, or in vitro.